Navigation Links
Trius Doses First Patient in Antibacterial Phase 2 Trial
Date:9/21/2008

TR-701 Tested for Efficacy in Drug Resistant Skin Infections

SAN DIEGO, Sept. 22 /PRNewswire/ -- Trius Therapeutics, Inc. today announced the initiation of Phase 2 testing of the oral form of its second-generation oxazolidinone antibacterial drug TR-701. The multicenter trial will test the efficacy, safety and tolerability of once-daily doses of 200, 300 and 400 milligrams of TR-701 in complicated skin and skin structure infections (cSSSI) for five to seven days of treatment.

The study follows the recently completed two-part Phase 1 study that tested the safety, tolerability and pharmacokinetics of TR-701 in single and multiple ascending doses for up to 21 days compared with Zyvox(R) (linezolid), the only marketed drug of the oxazolidinone class. In addition, separate food effect and microdialysis studies measuring the absorption of TR-701 in the presence and absence of food and the tissue penetration of the drug, respectively, have also been completed.

Results of the Phase 1 trials will be presented at the joint annual meetings of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) in Washington, D.C in October 2008.

"Our Phase 1 study results indicate that TR-701 will be a once-daily drug with the potential to offer patients several important advantages over linezolid as well as other marketed drugs," said Philippe Prokocimer, M.D., Chief Medical Officer of Trius. "The intent of Phase 2 will be to validate these observations in a patient population and to select a therapeutic dosing regimen from the three doses being tested."

"The growing epidemic of MRSA in the hospital and community leaves few viable treatment options for patients requiring an oral drug," said Jeffrey Stein, Ph.D., Chief Executive Officer of Trius. "We believe that the once-daily dosing and short course of TR-701 therapy of five to seven days will offer a clinical advantage fo
'/>"/>

SOURCE Trius Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. PacificGMP Completes GMP Product Fill for Trius Therapeutics
2. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
3. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
4. Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US
5. Video: Resveratrol-based Nutriceutical (Longevinex(R)) Induces Favorable Changes on Gene Expression in Mouse Heart At Doses 17-320 Times Lower Than Prior Studies
6. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
7. Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile
8. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
9. Emisphere Announces Second Study Demonstrating Dramatic Increases in Absorption of Oral B12 Using eligen(R) Technology at Lower Doses
10. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
11. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... N.J. and LOS ANGELES ... Diagnostics (NYSE: DGX ), the world,s leading ... it has completed the previously announced acquisition of ... As a result of the transaction, ... extensive range of innovative services and network of ...
(Date:8/4/2015)... 2015  Sutro Biopharma today announced that it ... vice president of alliance and project management. Dr. ... management of Sutro,s collaborative partnerships and the development ... bispecific antibodies and antibody-based therapeutics targeting immuno-oncology pathways. ... years of experience in the biopharmaceutical sector with ...
(Date:8/4/2015)... 4, 2015  Delcath Systems, Inc. (NASDAQ: DCTH ... on oncology with an emphasis on the treatment of ... summarizing data from studies in Europe ... Hepatic CHEMOSAT ® Delivery System (CHEMOSAT) will be presented ... congress, which will be held in Marseille, ...
Breaking Medicine Technology:Quest Diagnostics Completes Acquisition of MemorialCare Health System's Laboratory Outreach Service Business in Southern California 2Sutro Biopharma Appoints Nicki Vasquez, Ph.D. as VP of Alliance and Project Management 2Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 2Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 3Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 4
... Inc., a neurology-focused specialty pharmaceutical company, announced today that ... of CAMBIA™ (diclofenac potassium for oral solution) will be ... Neurology Conference (CONy) in Barcelona, Spain. The ... entitled, "Rapid and Sustained Improvement in Migraine Symptoms with ...
... joint guideline by the American Society of Hematology (ASH) ... physicians about the appropriate use of erythropoiesis-stimulating agents (ESAs), ... to produce more red blood cells, to treat cancer ... ESAs are associated with shorter survival and increased risk ...
Cached Medicine Technology:New Analysis of CAMBIA™ Pivotal Data to be Presented at the 4th World Congress on Controversies in Neurology 2New Analysis of CAMBIA™ Pivotal Data to be Presented at the 4th World Congress on Controversies in Neurology 3New Analysis of CAMBIA™ Pivotal Data to be Presented at the 4th World Congress on Controversies in Neurology 4New Guideline from ASH and ASCO Recommends Caution Regarding ESA Use in Cancer Patients 2New Guideline from ASH and ASCO Recommends Caution Regarding ESA Use in Cancer Patients 3
(Date:8/4/2015)... ... 2015 , ... Rhode Island Medical Imaging (RIMI) is pleased to announce the ... Wake Robin Road in Lincoln, RI. This satellite office will provide x-ray and ... out-patient x-ray hours in the state, which includes evenings and weekends. , “This ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... capsule formula. Healthy Origins® Cognizin® is a trademark for Citicoline, a nutrient ... for a capsule for those applications which have more of a semi-solid composition. ...
(Date:8/4/2015)... ... August 04, 2015 , ... Ryadon Inc. will ... Finding reliable hardware can be difficult and troublesome for companies. Without dependable ... or designing a new facility, it is imperative to include only the finest, ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... Angelina Jolie ... that affects millions of women every year. Dr. Angela DeRosa, DO, MBA, CPE ... hormone replacement therapies, takes the scary unknown out of menopause. , Myth #1: ...
(Date:8/4/2015)... , ... August 04, 2015 , ... ... the United States, Richard Carmona, M.D., M.P.H., FACS, to its Board of Directors ... and will save lives," Dr. Carmona said. "I strongly believe in the mission ...
Breaking Medicine News(10 mins):Health News:Rhode Island Medical Imaging Opens Satellite Imaging Center on Wake Robin Road in Lincoln 2Health News:Healthy Origins® Introduces Cognizin® Citicoline in a Vegetarian Capsule 2Health News:Healthy Origins® Introduces Cognizin® Citicoline in a Vegetarian Capsule 3Health News:Ryadon, Inc. is Now Offering their Ball Bearing Drawer Slides to Los Angeles, CA Commercial Customers 2Health News:Ryadon, Inc. is Now Offering their Ball Bearing Drawer Slides to Los Angeles, CA Commercial Customers 3Health News:Ryadon, Inc. is Now Offering their Ball Bearing Drawer Slides to Los Angeles, CA Commercial Customers 4Health News:"Dr. Hot Flash" Debunks the Top 5 Menopause Myths 2Health News:"Dr. Hot Flash" Debunks the Top 5 Menopause Myths 3Health News:Dr. Richard Carmona, 17th Surgeon General of the United States, Joins PerceptiMed, Inc.’s Board of Directors 2Health News:Dr. Richard Carmona, 17th Surgeon General of the United States, Joins PerceptiMed, Inc.’s Board of Directors 3
... , , New York ,s Automobile Insurance System Is Currently ... Feb. 3 Fraud and abuse in New York ... million in 2009, constituting a "fraud tax" of $1,561 , ... Hartwig , an economist and president of the Insurance Information Institute ...
... explain memory and other problems related to disorder, study ... with severe obstructive sleep apnea have reduced concentrations of ... research shows. , Gray matter refers to the brain,s ... place. These changes in brain structure may help explain ...
... DANVILLE, Pa. Feb. 3, 2010 The Translational Genomics ... signing of a strategic research agreement that provides for a ... research can make a difference. One of the first ... other metabolic conditions. Researchers plan to look at the possible ...
... AdvanceMarketWoRx ... ... and consumer healthcare marketers have a new resource to look to for advice on ... titled “Best Learning Actions for Healthcare Marketers in 2010,” is the first of its ...
... , Held at 2,000 U.S. locations during National ... Feb. 3 With an economy that might cause some ... decay being the most prevalent chronic disease in America,s children, the ... the eighth consecutive year in a national campaign to extend necessary ...
... , CLEVELAND , Feb. 3 Twenty ... a recent survey by Herbruck Alder, a Cleveland -based ...  This is an increase of seven percent over the results ... Third Annual Employer Wellness Survey, another 17 percent of respondents ...
Cached Medicine News:Health News:Inflated Medical Bills and Bogus Claims Drive Up Cost of No-Fault Auto Insurance in New York, I.I.I. Finds 2Health News:Inflated Medical Bills and Bogus Claims Drive Up Cost of No-Fault Auto Insurance in New York, I.I.I. Finds 3Health News:Inflated Medical Bills and Bogus Claims Drive Up Cost of No-Fault Auto Insurance in New York, I.I.I. Finds 4Health News:Brain Damage Seen in People With Severe Sleep Apnea 2Health News:TGen and Geisinger Health System announce strategic partnership 2Health News:TGen and Geisinger Health System announce strategic partnership 3Health News:Six Key Areas of Learning for Pharmaceutical and Healthcare Marketing in 2010 2Health News:Six Key Areas of Learning for Pharmaceutical and Healthcare Marketing in 2010 3Health News:Six Key Areas of Learning for Pharmaceutical and Healthcare Marketing in 2010 4Health News:Eighth Annual 'Give Kids A Smile' Day Provides Free Dental Care to Children 2Health News:Eighth Annual 'Give Kids A Smile' Day Provides Free Dental Care to Children 3Health News:Herbruck Alder Survey Reveals More Northern Ohio Companies Offering Employee Wellness Programs 2Health News:Herbruck Alder Survey Reveals More Northern Ohio Companies Offering Employee Wellness Programs 3
Angled 40 Degrees, 0.6x0.8 Elliptical Tip; in Titanium...
Double ended with 0.5mm x 10mm and 1.0mm x 15mm blades; both blades gently curved; round serrated handle, In Titanium....
Bend with "H" Shaped Tip, LEFT; in Titanium....
0.6mm Tip x10mm Shaft, Gently Curved From Tip to Bend, 90 Degree Hook at Tip; overall length 120mm; in Titianium....
Medicine Products: